<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375570</url>
  </required_header>
  <id_info>
    <org_study_id>609-07</org_study_id>
    <nct_id>NCT00375570</nct_id>
  </id_info>
  <brief_title>Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents</brief_title>
  <official_title>An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medivir</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medivir</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to evaluate the safety of ME-609 for the treatment of recurrent
      herpes labialis in adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study was to evaluate the safety of ME-609 for the treatment of herpes
      labialis recurrences in immunocompetent adolescents, 12 - 17 years of age, following a 5-day
      treatment with 5-time daily topical administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>3 weeks after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ME-609</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ME-609</intervention_name>
    <description>Topical treatment 5 times daily for 5 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General good health

          -  History of recurrent herpes labialis with at two recurrences during the last twelve
             months

        Exclusion Criteria:

          -  Treatment with systemic or topical antiviral agents or steroids within two weeks prior
             to inclusion

          -  Significant skin condition that occur in the area of herpes recurrences

          -  Nursing or/and pregnancy

          -  Immunosupressed state due to underlying disease (e.g. HIV infection or concomitant
             treatment (e.g. cancer chemotherapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Strand, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Sciences, Dermatology and Venereology University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <last_update_submitted>August 14, 2008</last_update_submitted>
  <last_update_submitted_qc>August 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Borje Darpo, MD, PhD</name_title>
    <organization>Medivir AB</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

